APOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban
Clocchiatti-Tuozzo S, Rivier C, Renedo D, Huo S, de Havenon A, Hawkes M, Gilmore E, Schwamm L, Sheth K, Gill T, Falcone G. APOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban. JAMA Neurology 2025, 82: 808-816. PMID: 40549373, PMCID: PMC12186128, DOI: 10.1001/jamaneurol.2025.0182.Peer-Reviewed Original ResearchRisk of intracranial hemorrhagePopulation-based studyYears of follow-up dataApo E4Cox proportional hazards modelsAPOE e4 alleleIntracranial hemorrhageRisk prediction scoreCerebral amyloid angiopathyClinical decision-makingProportional hazards modelAtrial fibrillationIncreased risk of ICHMultivariate Cox proportional hazards modelMain OutcomesIncident intracranial hemorrhageEuropean ancestryCohort studyInclusion criteriaHistory of ischemic strokeAmyloid angiopathyE4 variantHazards modelIncreased riskE4 allelePolygenic Risk Factor Profiling and Risk of Intracerebral Hemorrhage In Patients with Atrial Fibrillation on Apixaban (P9-13.008)
Clocchiatti-Tuozzo S, Rivier C, Huo S, Gilmore E, Shoamanesh A, Kamel H, Murthy S, Ohno-Machado L, Sheth K, Gill T, Falcone G. Polygenic Risk Factor Profiling and Risk of Intracerebral Hemorrhage In Patients with Atrial Fibrillation on Apixaban (P9-13.008). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000212525.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply